279 related articles for article (PubMed ID: 15481318)
1. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Sapienza MS; Cohen S; Dimarino AJ
Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
4. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
[TBL] [Abstract][Full Text] [Related]
6. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
[TBL] [Abstract][Full Text] [Related]
7. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
Batres LA; Mamula P; Baldassano RN
J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
[No Abstract] [Full Text] [Related]
8. Infliximab for peristomal pyoderma gangrenosum.
Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
10. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
[TBL] [Abstract][Full Text] [Related]
11. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.
Teich N
Tech Coloproctol; 2014 Oct; 18(10):965-6. PubMed ID: 24965074
[No Abstract] [Full Text] [Related]
12. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
14. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
15. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
16. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery.
Andrisani G; Guidi L; Papa A; Potenza AE; Cervelli D; Armuzzi A
J Crohns Colitis; 2013 Jun; 7(5):421-6. PubMed ID: 22889645
[TBL] [Abstract][Full Text] [Related]
17. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
19. Peristomal pyoderma gangrenosum and inflammatory bowel disease.
Cairns BA; Herbst CA; Sartor BR; Briggaman RA; Koruda MJ
Arch Surg; 1994 Jul; 129(7):769-72. PubMed ID: 7912923
[TBL] [Abstract][Full Text] [Related]
20. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
